alectinib
Also known as AF802, Alecensa®, CH5424802, CH 5424802, AF-802, AF 802, Alecensa, 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile
Alectinib (INN), sold under the brand name Alecensa, is an anticancer medication that is used to treat non-small-cell lung cancer (NSCLC). It blocks the activity of anaplastic lymphoma kinase (ALK). It is taken by mouth. It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group.
Key facts
- Drug.DrugBank
- DB11363
- Drug.image
- Alectinib structure.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 275
- Drug.JAN
- alectinib hydrochloride
- Drug.tradename
- Alecensa
- Drug.MedlinePlus
- a616007
- Drug.DailyMedID
- Alectinib
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- ED03
- Drug.legal_AU
Article
13 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- History
- Society and culture
- Legal status
- References
- External links
Alectinib (INN), sold under the brand name Alecensa, is an anticancer medication that is used to treat non-small-cell lung cancer (NSCLC). It blocks the activity of anaplastic lymphoma kinase (ALK). It is taken by mouth. It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group.
The most common side effects include constipation, muscle pain and edema (swelling) including of the ankles and feet, the face, the eyelids and the area around the eyes.
Connections
Categories
4-Morpholinyl compoundsCarbazolesChemical articles with multiple CAS registry numbersChemicals using indexlabelsDrugs developed by GenentechDrugs developed by Hoffmann-La RocheDrugs with non-standard legal statusECHA InfoCard ID from WikidataInfobox drug with local INN variantKetonesMultiple chemicals in Infobox drugNitriles